Ensysce Biosciences announces continued enrollment in PF614-MPAR trial

Ensysce Biosciences (ENSC) announced continued subject enrollment and successful dosing augmenting the progress of its second clinical trial to evaluate PF614-MPAR for overdose protection. In the current study of PF614-MPAR-102, data showed that a 100 mg dosage form of PF614-MPAR provides overdose protection when a greater-than-prescribed dose is consumed at one time. The study has continued with enrollment of the highest dosing cohort of 5 times the 100 mg dose unit. Importantly, adverse events have been limited, thus far verifying the favorable safety profile of PF614 and PF614-MPAR as a novel class of opioids to treat severe pain.